CME Information: Neuropsychiatric Sequelae Part 1
Neuropsychiatric Sequelae Virtual Curriculum Series: Agitation, Depression, and Pseudobulbar Affect Part I
This educational activity is supported by an educational grant from Avanir Pharmaceuticals, Inc.
The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENTS
Live Internet Activity
Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program
DATE OF RELEASE/EXPIRATION
Tuesday, April 4, 2017, from 1:00 PM EST – 2:00 PM EST
The enduring material will be available from April 4, 2017 to June 23, 2018.
At the conclusion of this activity, participants will be able to:
|•||Identify different and various forms of agitation among patients with Alzheimer’s disease (AD).|
|•||Review proposed mechanisms underlying agitation in AD and how pharmacologic agents may affect them|
|•||Evaluate body of evidence of current and emerging pharmacologic agents for the management of agitation/aggression in patients with AD|
US-based neurologists, psychiatrists, geriatricians, primary care clinicians (internal, general and family medicine), and health care providers involved in the care of patients with neuropsychiatric sequelae who may be suffering from agitation as a result of Alzheimer’s disease (AD).
ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.
METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that this module will take approximately 1 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
|George T. Grossberg, MD||
Consulting Fee: Acadia; Allergan; Avanir; Axovant; Lundbeck; Novartis; Otsuka; Takeda
|David Beck, MD||
Dr. Beck has nothing to disclose relevant to this activity
|David M. Kaufman, MD||Has nothing to disclose relevant to this activity.|
|Einstein-Montefiore Center for Continuing Medical Education||The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity.|
|PlatformQ Health Education, LLC||Disclsoures|
|Anne Roc, PhD, Medical Director||Has nothing to disclose relevant to this activity|
|Karen Greb–Murphy, Program Manager||Has nothing to disclose relevant to this activity.|
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to email@example.com.
DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, NeuroSeriesLive, PsychiatryCareLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.